Research programme: ethylenedicysteine glucosamine drug conjugates - CellPointAlternative Names: 187 Re ethylenedicysteine glucosamine; 187-Re-EC-G; Platinum ethylenedicysteine glucosamine; Platinum-EC-G; Re-187-EC-G
Latest Information Update: 05 Feb 2014
At a glance
- Originator CellPoint
- Class Drug conjugates; Organometallic compounds
- Mechanism of Action Apoptosis stimulants; DNA cross linking agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical B cell lymphoma